Study to Assess the Comparative Bioavailability and Pharmacokinetics of Naproxen From OXP005 Tablets (Test) And Naprosyn Tablets (Reference) in Normal, Healthy, Adult Subjects

Trial Profile

Study to Assess the Comparative Bioavailability and Pharmacokinetics of Naproxen From OXP005 Tablets (Test) And Naprosyn Tablets (Reference) in Normal, Healthy, Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2015

At a glance

  • Drugs Naproxen (Primary)
  • Indications Musculoskeletal pain
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors Oxford Pharmascience
  • Most Recent Events

    • 13 May 2015 Positive full results of the pilot comparative pharmacokinetic study published in Oxford Pharmascience media release.
    • 27 Mar 2015 Primary endpoint has been met (comparative bioavailability of naproxen as measured by Tmax, Cmax, AUC, half-life), according to an Oxford Pharmascience media release.
    • 27 Mar 2015 Status changed from recruiting to completed, as reported in an Oxford Pharmascience media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top